Trial · NCT00896779

Lucentis in Advanced Macular Degeneration

NCT00896779, Phase 2, Completed, Steven R. Sanislo; results first posted 2015-05-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Lucentis in Advanced Macular Degeneration. Trials, record NCT00896779. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00896779

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Lucentis in Advanced Macular Degeneration
NCT number: NCT00896779
Status: Completed
Phases: Phase 2
Enrollment: 20 participants, actual
Lead sponsor: Steven R. Sanislo
Conditions: Macular Degeneration
Interventions: ranibizumab
First posted: 2009-05-12
Last updated: 2015-06-29
Results first posted: 2015-05-27
Limitations and caveats: Limitations include small number of subjects analyzed and no control group that were untreated.

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean Change in Visual Acuity	12 months	Change in vision from baseline measurement at 12 months. Standard ETDRS chart (80 letters) was used to determine visual acuity with test luminance of 45 cd/m \^2 at 8 feet. Number of correctly read letters were reported.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Mean Change in Visual Acuity	12 months		letters	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Mean Change in Visual Acuity	Ranibizumab Group 1		15.0	Standard Deviation 14.2	letters
Mean Change in Visual Acuity	Ranibizumab Group 2		5.6	Standard Deviation 8.6	letters

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ranibizumab Group 1	8
Overall Study	STARTED	Ranibizumab Group 2	12
Overall Study	COMPLETED	Ranibizumab Group 1	8
Overall Study	COMPLETED	Ranibizumab Group 2	11
Overall Study	NOT COMPLETED	Ranibizumab Group 1	0
Overall Study	NOT COMPLETED	Ranibizumab Group 2	1

Source ClinicalTrials.gov

Adverse events38

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	laceration right leg	Skin and subcutaneous tissue disorders	Ranibizumab Group 1	1	8
other	laceration right leg	Skin and subcutaneous tissue disorders	Ranibizumab Group 2	0	12
other	laceration left leg	Skin and subcutaneous tissue disorders	Ranibizumab Group 1	1	8
other	laceration left leg	Skin and subcutaneous tissue disorders	Ranibizumab Group 2	0	12
other	Mild pneumonia	Respiratory, thoracic and mediastinal disorders	Ranibizumab Group 1	1	8
other	Mild pneumonia	Respiratory, thoracic and mediastinal disorders	Ranibizumab Group 2	0	12
other	Seasonal allergies	Immune system disorders	Ranibizumab Group 1	1	8
other	Seasonal allergies	Immune system disorders	Ranibizumab Group 2	0	12
other	Worsening glaucoma - which eye was not specified	Eye disorders	Ranibizumab Group 1	1	8
other	Worsening glaucoma - which eye was not specified	Eye disorders	Ranibizumab Group 2	0	12

1 to 10 of 38Source ClinicalTrials.gov

See all 38 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ranibizumab Group 1
Total, all-cause mortality	Ranibizumab Group 2
Total, other adverse events	Ranibizumab Group 1	4	8
Total, other adverse events	Ranibizumab Group 2	4	12
Total, serious adverse events	Ranibizumab Group 1	0	8
Total, serious adverse events	Ranibizumab Group 2	0	12

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Ranibizumab Group 1 vs Ranibizumab Group 2: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00896779

GET https://conductscience.org/api/trials/v1/NCT00896779/events?page=2

API reference For AI assistants